Tevogen CEO Donates Shares to Support Education for Underprivileged Children

Rhea-AI Summary

Tevogen (Nasdaq: TVGN) announced on December 22, 2025 that Founder and CEO Dr. Ryan Saadi donated 230,000 shares of Tevogen common stock to SRLC USA, a United Nations-recognized 501(c)(3) nonprofit serving underserved communities.

The company said the transfer was conducted in accordance with SEC Rule 144 and that Dr. Saadi will not receive any proceeds from any disposal of the securities. The donation is described as supporting education initiatives for underprivileged children.

Key Figures

Q3 2025 net loss $5,726,812 Quarter ended September 30, 2025 (424B3/10‑Q)

Nine‑month net loss $21,597,852 Nine months ended September 30, 2025 (424B3)

Cash balance $1,037,094 As of September 30, 2025 (424B3/10‑Q)

ATM program size $50,000,000 At‑the‑market Sales Agreement entered July 3, 2025

ATM net proceeds $3.9 million Through November 12, 2025 (424B3/10‑Q)

Loan outstanding $4,400,000 Unsecured related‑party Loan Agreement balance

Credit line remaining $21,000,000 Available under related‑party line of credit as of Q3 2025

Grant commitment $7.0 million KRHP grants committed beyond year‑to‑date funding

Market Reality Check

$0.0419 Last Close

Volume Volume 1,028,384 vs 20‑day average 1,418,425, indicating lighter than usual trading ahead of this filing‑type news. normal

Technical Price at $0.3797, trading below 200‑day MA of $0.92 and 80.22% under the 52‑week high of $1.92.

Peers on Argus 2 Up

TVGN was near flat (-0.26%) while peers showed mixed strength: KYTX and CRBU were up (1.7%, 2.44%) and VTYX gained 12.05%, suggesting this insider donation headline was stock‑specific rather than part of a sector‑wide move.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 11	Philanthropic donation	Positive	-1.8%	CEO donated 230,000 personal shares to local P.B.A. charity.
Dec 09	Management recognition	Positive	+3.5%	Yale honor for board member tied to education and equity contributions.
Dec 08	Recognition & outlook	Positive	+8.8%	NJBIZ Power List recognition and multi‑billion‑dollar revenue outlook.
Nov 14	Quarterly results	Negative	-6.1%	Q3 2025 10‑Q showing ongoing net losses and tight liquidity.
Nov 05	Clinical milestone	Positive	-5.4%	Expanded HLA coverage and strong proof‑of‑concept COVID trial data.

Pattern Detected

Recent news shows mixed alignment: philanthropic and clinical milestones have sometimes seen divergent price reactions, while operational and recognition items more often aligned positively.

Recent Company History

Over the last few months, Tevogen has combined philanthropic visibility with operational and clinical updates. On Nov 5, 2025, it reported a major COVID T‑cell milestone with 100% viral clearance, yet shares fell 5.42%. Q3 results on Nov 14, 2025 highlighted a net loss of $5.73 million and tight liquidity, with a 6.12% decline. In December, recognition on the 2025 New Jersey Power List and revenue outlook of up to $22 billion coincided with gains of 8.81% and 3.46%, while a prior 230,000‑share charitable gift saw a modest 1.78% pullback.

Market Pulse Summary

This announcement details another charitable gift of 230,000 CEO shares under SEC Rule 144, echoing earlier insider philanthropy without altering Tevogen’s fundamentals. Recent filings show a Q3 net loss of $5.73 million, cash of $1.04 million, and reliance on a $50 million ATM and related‑party credit. Investors tracking this name often focus on liquidity, clinical progress, and execution against its stated multi‑billion‑dollar revenue outlook.

Key Terms

501(c)(3) regulatory

"a United Nations-recognized 501(c)(3) nonprofit organization dedicated to serving"

A 501(c)(3) is a U.S. federal tax designation for organizations organized and operated for charitable, educational, religious, scientific or literary purposes, which exempts them from federal income tax and generally makes donations to them tax-deductible. Investors pay attention because the designation shapes how the organization raises money, what activities it can legally pursue (for example, limits on political lobbying), and how transparent and financially stable it must be—factors that affect risk, reputation, and potential partnerships.

sec rule 144 regulatory

"The donation was conducted in accordance with SEC Rule 144 and Dr. Saadi"

SEC Rule 144 is a U.S. securities regulation that sets the conditions under which holders of restricted or control stock can publicly sell their shares. Think of it as traffic rules for selling large or previously locked-up blocks of stock: it imposes waiting periods, limits on how much can be sold at once, requires that enough public information about the issuer be available, and may require a notice filing, all of which affect how quickly and smoothly investors can convert shares to cash without unsettling the market.

AI-generated analysis. Not financial advice.

WARREN, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced that its Founder and CEO, Dr. Ryan Saadi has made a charitable contribution of 230,000 shares of Tevogen common stock to SRLC USA, a United Nations-recognized 501(c)(3) nonprofit organization dedicated to serving underserved communities.

“Education is one of the most powerful long-term investments we can make in building healthier, more equitable societies,” said Dr. Saadi. “I’m pleased to support an organization that is deeply committed to uplifting underserved communities through meaningful, measurable action.”

The donation was conducted in accordance with SEC Rule 144 and Dr. Saadi will not receive any proceeds from the disposal of the securities.

About Tevogen

Tevogen is a next-generation, socially integrated healthcare enterprise built on the principles of affordability, efficiency, and scientific rigor. The company leverages industry-leading artificial intelligence and precision T cell therapy platforms, a patient-first and cost-disciplined operating model, and strategic engagements with global technology leaders to support the development of advanced, life-saving therapies across multiple therapeutic areas and scalable solutions for the broader healthcare system.

Tevogen Bio, the company’s lead initiative, has completed a proof-of-concept clinical trial demonstrating the potential of its single-HLA-restricted, genetically unmodified allogeneic T cells. The Tevogen Bio pipeline spans virology, oncology, and neurology, with programs built on the company’s proprietary ExacTcell™ platform.

Tevogen.AI is designed to transform drug development by accelerating target detection, helping reduce failure rates, and supporting optimized clinical trial design through proprietary predictive technologies. The platform utilizes cloud and data services from leading technology providers, including Microsoft and Databricks, to advance its long-term ambition to predict the proteome for any given protein–HLA combination, enabling rapid and cost-efficient therapeutic discovery.

Tevogen is exploring future strategic initiatives that may include domestic generics, biosimilars, medical devices, and innovative insurance solutions for healthcare providers. Together, these programs reflect Tevogen’s mission to advance sustainable innovation and broaden patient access through a faster, more efficient, and more equitable healthcare model.

Forward Looking Statements

This press release contains certain forward-looking statements, including without limitation statements relating to: Tevogen’s plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.

Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; that Tevogen will need to raise additional capital to fully realize its business plans; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s Annual Report on Form 10-K and subsequent filings with the SEC.

You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.

Contacts

Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a79913bb-5354-496c-911d-2f8215cad958

FAQ

What did Tevogen announce on December 22, 2025 regarding CEO Dr. Ryan Saadi and TVGN shares?

Dr. Ryan Saadi donated 230,000 shares of Tevogen common stock to SRLC USA; the transfer followed SEC Rule 144 and he will not receive proceeds.

Who is the recipient SRLC USA and what is the purpose of the TVGN share donation?

SRLC USA is a United Nations-recognized 501(c)(3) nonprofit; the donation is intended to support education for underserved children.

Will Dr. Ryan Saadi receive money from the 230,000 TVGN shares donated on December 22, 2025?

No; the company stated Dr. Saadi will not receive any proceeds from disposal of the donated securities.

Was the TVGN share donation by Tevogen’s CEO compliant with securities rules?

Yes; the company said the donation was conducted in accordance with SEC Rule 144.

How might the December 22, 2025 donation of 230,000 TVGN shares affect Tevogen shareholders?

The announcement states a transfer of existing shares by the CEO; no issuance or cash transaction was reported, and no direct dilution was disclosed.

Where can investors find details about the TVGN share donation by Tevogen’s CEO?

Investors can refer to Tevogen disclosures and SEC filings for complete transfer details and any related insider reporting.